Skip to content

Study · Animal study (in vivo) · mouse · 2026

10 results

The Synthetic Melanocortin Agonist NDP-MSH Ameliorates THSD7A-Associated Membranous Nephropathy in an Active Immunization Mouse Model.

Zhang M, Chen M, Ge Y, Gunning W, Gong R

FASEB journal : official publication of the Federation of American Societies for Experimental Biology1 Jul 2026

PMID42394403 (opens in a new tab)PMCIDPMC13329422 (opens in a new tab)DOI10.1096/fj.202600817r (opens in a new tab)PepBankPUB-42394403
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with THSD7A-associated membranous nephropathy, rescue treatment with NDP-MSH significantly reduced proteinuria.

    In plain wordsIn mice with a kidney disease model, NDP-MSH lowered protein in the urine.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseProteinuria
    Study

    mousen: not reported in source

    THSD7A active immunization model of membranous nephropathy
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Rescue treatment with the pan-melanocortin receptor agonist NDP-MSH significantly reduced proteinuria and mitigated glomerular damage and podocyte injury.
    1 context sentence
    Summary · context
    To address this gap, we established an active immunization model of THSD7A-associated MN by immunizing mice with recombinant THSD7A antigen.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with THSD7A-associated membranous nephropathy, rescue treatment with NDP-MSH mitigated glomerular damage.

    In plain wordsIn mice with a kidney disease model, NDP-MSH reduced damage to the kidney filters.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseGlomerular damage
    Study

    mousen: not reported in source

    THSD7A active immunization model of membranous nephropathy
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Rescue treatment with the pan-melanocortin receptor agonist NDP-MSH significantly reduced proteinuria and mitigated glomerular damage and podocyte injury.
    1 context sentence
    Summary · context
    To address this gap, we established an active immunization model of THSD7A-associated MN by immunizing mice with recombinant THSD7A antigen.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with THSD7A-associated membranous nephropathy, rescue treatment with NDP-MSH mitigated podocyte injury.

    In plain wordsIn mice with a kidney disease model, NDP-MSH reduced injury to kidney filter cells.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreasePodocyte injury
    Study

    mousen: not reported in source

    THSD7A active immunization model of membranous nephropathy
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Rescue treatment with the pan-melanocortin receptor agonist NDP-MSH significantly reduced proteinuria and mitigated glomerular damage and podocyte injury.
    1 context sentence
    Summary · context
    To address this gap, we established an active immunization model of THSD7A-associated MN by immunizing mice with recombinant THSD7A antigen.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with THSD7A-associated membranous nephropathy, NDP-MSH treatment markedly reduced circulating anti-THSD7A autoantibody levels.

    In plain wordsIn mice with a kidney disease model, NDP-MSH lowered blood levels of the harmful autoantibody.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseCirculating anti-THSD7A autoantibody
    Study

    mousen: not reported in source

    THSD7A active immunization model of membranous nephropathy
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This was accompanied by a marked reduction in circulating anti-THSD7A autoantibody levels, reduced glomerular immune deposition, and diminished complement activation.
    2 context sentences
    Summary · context
    Rescue treatment with the pan-melanocortin receptor agonist NDP-MSH significantly reduced proteinuria and mitigated glomerular damage and podocyte injury.
    Summary · context
    To address this gap, we established an active immunization model of THSD7A-associated MN by immunizing mice with recombinant THSD7A antigen.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with THSD7A-associated membranous nephropathy, NDP-MSH treatment reduced glomerular immune deposition.

    In plain wordsIn mice with a kidney disease model, NDP-MSH reduced immune deposits in the kidney filters.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseGlomerular immune deposition
    Study

    mousen: not reported in source

    THSD7A active immunization model of membranous nephropathy
    Outcome group
    Immune response · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This was accompanied by a marked reduction in circulating anti-THSD7A autoantibody levels, reduced glomerular immune deposition, and diminished complement activation.
    2 context sentences
    Summary · context
    Rescue treatment with the pan-melanocortin receptor agonist NDP-MSH significantly reduced proteinuria and mitigated glomerular damage and podocyte injury.
    Summary · context
    To address this gap, we established an active immunization model of THSD7A-associated MN by immunizing mice with recombinant THSD7A antigen.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with THSD7A-associated membranous nephropathy, NDP-MSH treatment diminished complement activation.

    In plain wordsIn mice with a kidney disease model, NDP-MSH lowered complement activation.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseComplement activation
    Study

    mousen: not reported in source

    THSD7A active immunization model of membranous nephropathy
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This was accompanied by a marked reduction in circulating anti-THSD7A autoantibody levels, reduced glomerular immune deposition, and diminished complement activation.
    2 context sentences
    Summary · context
    Rescue treatment with the pan-melanocortin receptor agonist NDP-MSH significantly reduced proteinuria and mitigated glomerular damage and podocyte injury.
    Summary · context
    To address this gap, we established an active immunization model of THSD7A-associated MN by immunizing mice with recombinant THSD7A antigen.
  7. 07LabEx vivo tissueMechanism

    In primed B cells from mice with membranous nephropathy, ex vivo NDP-MSH directly inhibited plasma cell differentiation.

    In plain wordsIn lab tests on mouse B cells, NDP-MSH blocked their change into antibody-making cells.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreasePlasma cell differentiation
    Study

    mousen: not reported in source

    primed B cells isolated from diseased mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, ex vivo treatment of primed B cells isolated from diseased mice demonstrated that NDP-MSH directly inhibited plasma cell differentiation and autoantibody production.
  8. 08LabEx vivo tissueMechanism

    In primed B cells from mice with membranous nephropathy, ex vivo NDP-MSH directly inhibited autoantibody production.

    In plain wordsIn lab tests on mouse B cells, NDP-MSH reduced autoantibody production.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseAutoantibody production
    Study

    mousen: not reported in source

    primed B cells isolated from diseased mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, ex vivo treatment of primed B cells isolated from diseased mice demonstrated that NDP-MSH directly inhibited plasma cell differentiation and autoantibody production.
  9. 09LabEx vivo tissueMechanism

    In primed B cells from mice with membranous nephropathy, NDP-MSH increased expression of microphthalmia-associated transcription factor (MITF).

    In plain wordsIn lab tests on mouse B cells, NDP-MSH raised the level of the MITF protein.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseMITF expression
    Study

    mousen: not reported in source

    primed B cells isolated from diseased mice
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This suppression was accompanied by increased expression of microphthalmia-associated transcription factor (MITF) and downregulation of interferon regulatory factor 4 (IRF4), indicating activation of the MITF/IRF4 signaling axis, a pathway implicated in negative regulation of B cell differentiation.
  10. 10LabEx vivo tissueMechanism

    In primed B cells from mice with membranous nephropathy, NDP-MSH downregulated interferon regulatory factor 4 (IRF4).

    In plain wordsIn lab tests on mouse B cells, NDP-MSH lowered the level of the IRF4 protein.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseIRF4 expression
    Study

    mousen: not reported in source

    primed B cells isolated from diseased mice
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This suppression was accompanied by increased expression of microphthalmia-associated transcription factor (MITF) and downregulation of interferon regulatory factor 4 (IRF4), indicating activation of the MITF/IRF4 signaling axis, a pathway implicated in negative regulation of B cell differentiation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.